Atrium Therapeutics Inc (NASDAQ: RNA) is a clinical-stage biopharmaceutical company developing product candidates targeting rare and genetically defined cardiac diseases. Revenue, where it exists, comes from collaboration agreements rather than product sales, as no product candidates had received regulatory approval as of the 10-Q filed May 14, 2026. The company completed a spin-off transaction and issued common stock in connection with that separation, as reflected in the Q1 2026 financial statements. Atrium is classified as a smaller reporting company and an emerging growth company under the JOBS Act, meaning it had not yet exceeded $1.235 billion in annual revenues as of the filing date. CEO Kathleen Gallagher and CFO Brendan Winslow signed the 10-Q filed May 14, 2026. The company targets small patient populations with rare cardiac indications, with stated plans to expand into broader patient populations after initial programs.

Revenue model

Collaboration revenue is the disclosed revenue line in the condensed statements of operations for the three months ended March 31, 2026 and March 31, 2025. The company reported net losses in both periods. No product revenue was disclosed, consistent with pre-commercialization status.

Products and services

Product candidates targeting rare and genetically defined cardiac diseases, with plans to expand into broader cardiac patient populations. No approved products were disclosed in the filing excerpts.

Customers and end markets

Target end markets are rare and genetically defined cardiac disease patient populations, initially small in size. Commercial viability in these markets depends on reimbursement from Medicare, Medicaid, private health insurers, and other third-party payors, as disclosed in the 10-Q filed May 14, 2026.

Value-chain role

Clinical-stage drug developer operating upstream of commercialization. The company conducts clinical trials, including in the European Economic Area, and is subject to GDPR requirements for clinical trial participant data. No manufacturing or distribution activities were described in the filing excerpts.

Geographic exposure

United States-based operations with clinical trial activity in the European Economic Area, as referenced in GDPR compliance disclosures in the 10-Q filed May 14, 2026.

Source: SEC 10-Q, filed 2026-05-14

Industry: Pharmaceutical Preparations